Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Cagrilintide
AM833, CagriSema (in combination with semaglutide)
Retatrutide
LY3437943, Eli Lilly Triple Agonist
A long-acting amylin analog developed by Novo Nordisk. Amylin is a hormone co-secreted with insulin that regulates appetite and gastric emptying. Being developed both standalone and in combination with semaglutide (CagriSema) — a combination showing weight loss exceeding 22% in Phase 3 trials, potentially the next step beyond tirzepatide.
An investigational triple-agonist peptide developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials are underway, with early results showing unprecedented weight loss efficacy.
Activates amylin receptors (CALCR/RAMP) in the brain, particularly in the area postrema and hypothalamus, reducing appetite through a pathway distinct from GLP-1. The combination with semaglutide targets two separate appetite-regulating systems simultaneously, producing additive weight loss beyond either agent alone.
Activates three metabolic hormone receptors: GLP-1 (appetite suppression, insulin secretion), GIP (enhanced insulin response, fat metabolism), and glucagon (increased energy expenditure, fat oxidation). The triple mechanism may produce greater weight loss than dual agonists.
- Weight management (investigational)
- Type 2 diabetes (investigational)
- Metabolic syndrome
- Weight management (investigational)
- Type 2 diabetes (investigational)
- Metabolic syndrome (investigational)
- GI side effects (nausea, vomiting) — similar to GLP-1 class
- Still in Phase 3 trials — full safety profile not established
- Injection site reactions
- Long-term effects unknown
- Still in clinical trials — full safety profile unknown
- GI side effects (nausea, diarrhea, vomiting) reported in trials
- Not yet approved for any indication
- Long-term effects unknown
Currently in Phase 3 trials as CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg). Phase 3 REDEFINE 1 trial showed ~22.7% weight loss at 68 weeks. Potential FDA submission 2026-2027. Represents the next generation beyond tirzepatide in the weight management pipeline.
Currently in Phase 3 clinical trials. Phase 2 results showed up to 24% body weight loss at 48 weeks. FDA approval timeline uncertain but potentially 2027-2028.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.